This page brings together the Agency's latest information on diabetes. It lists:
Xultophy is a medicine that is used for the treatment of type 2 diabetes. Together with diet and exercise, Xultophy is added to treatment with diabetes medicines taken by mouth when these medicines,...
This is a summary of the European public assessment report (EPAR) for Ristaben. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in...
This is a summary of the European public assessment report (EPAR) for Lyxumia. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in...
This is a summary of the European public assessment report (EPAR) for Fiasp. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is...
This is a summary of the European public assessment report (EPAR) for Lantus. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in...
EMA’s human medicines committee (CHMP) has recommended granting an extension of indication to Victoza (liraglutide) to include the treatment of children and adolescents aged 10 years or older with type 2 diabetes. This medicine is already approved...
EMA’s human medicines committee (CHMP) has recommended for the first time an adjunct treatment to insulin in the form of a tablet for certain patients with type 1 diabetes mellitus. Dapagliflozin is already authorised in the European Union as...
Diabetes patients reminded of importance of preventative foot care The European Medicines Agency (EMA) is informing about a potential increased risk of lower limb amputation (mostly affecting the toes) in patients taking the SGLT2 inhibitors...
Recommendations for patients with kidney impairment updated in product information The European Medicines Agency (EMA) has concluded that metformin-containing medicines can now be used in patients with moderately reduced kidney function (GFR [...
Healthcare professionals should be aware of possible atypical cases The European Medicines Agency (EMA) has confirmed recommendations 1 to minimise the risk of diabetic ketoacidosis in patients taking SGLT2 inhibitors (a class of type 2 diabetes...
Healthcare professionals should be aware of possible atypical cases EMA's Pharmacovigilance Risk Assessment Committee (PRAC) has finalised a review of SGLT2 inhibitors (a class of type 2 diabetes medicines) and has made recommendations to minimise...